Ildong Holdings Q1 2026: Revenue +5.5%, Operating Profit Positive, Dividend Maintained, Merger of Ildong Pharm and Yunovia

Consolidated Q1 2026 revenue 148.9B won (+5.5% YoY), operating profit 8.9B won
Parent standalone revenue 8.4B won (+82.1% YoY), operating profit 3.0B won
Final dividend of 100 won per share for FY2025, total 1.15B won
Board resolved in April 2026 to merge Ildong Pharmaceutical with Yunovia (effective June 16)
Xocova (COVID-19 treatment) under FDA review (PDUFA June 16, 2026); Japan approved prophylactic indication (Mar 23, 2026)
P-CAB for GERD in phase 3 clinical trial
Consolidated adjusted debt ratio improved to 31.9% from 35.15% at year-end 2025
Consolidated retained earnings negative at -116.5B won, but parent retains positive
Equity method loss from Ideence subsidiary of 2.1B won; net equity negative
14 lawsuits pending (6 as plaintiff, 8 as defendant) with total claim amount of 13.9B won
Contingent liabilities: put options related to Ideence convertible preferred shares and Ildong Bioscience stake sale